Racial differences in real-world outcomes of first-line therapies for advanced renal cell carcinoma

Daniel M. Geynisman, William S. John, Taavy A. Miller, Parisa Asgarisabet, Sarah B. Guttenplan, Xin Yin, Kristin M. Zimmerman Savill, Lindsay Mcallister, Lisa Rosenblatt

Research output: Contribution to journalArticlepeer-review

Abstract

BACKGROUND: Given the historical underrepresentation of racial minorities in clinical trials, little is known about racial differences in outcomes of first-line therapies for advanced renal cell carcinoma (aRCC). This study described patient characteristics and clinical outcomes of first-line therapies for aRCC, including nivolumab + ipilimumab, pembrolizumab + axitinib, and tyrosine kinase inhibitors, by race in the real-world setting.

METHODS: We conducted a retrospective medical chart review of patients with intermediate/poor-risk clear-cell aRCC. Treating physicians abstracted patient data from electronic medical charts.

RESULTS: Among 346 patients with intermediate/poor-risk aRCC, a higher proportion of African-American/Black (n = 78) versus White (n = 268) patients had poorer baseline functional performance (ECOG-PS ≥ 2: 37.2% versus 21.3%). African-American/Black patients trended toward numerically lower overall response rates and shorter overall survival for nivolumab + ipilimumab or pembrolizumab + axitinib than White patients.

CONCLUSIONS: These findings provide important insights into racial differences in first-line aRCC treatment outcomes within real-world settings. Additional research with larger sample sizes is warranted.

Original languageEnglish
Number of pages5
JournalOncologist
Early online dateNov 19 2024
DOIs
StatePublished - Dec 19 2024

Keywords

  • Ethnic and racial minorities
  • Nivolumab
  • Pembrolizumab
  • Renal cell carcinoma
  • Tyrosine kinase inhibitors

Fingerprint

Dive into the research topics of 'Racial differences in real-world outcomes of first-line therapies for advanced renal cell carcinoma'. Together they form a unique fingerprint.

Cite this